$NVO - PE is 10 and 35% net profit.

Summary

• The author highlights Novo Nordisk ($NVO) as a value play with a P/E of 10 and net profit margins above 35%.
• Thesis: solid revenue/earnings growth, long-tenured CEO, and low valuation create an attractive entry.
• Quality assessment: Speculative noise; lacks deep financial analysis or competitive moat discussion, relies on superficial metrics and a humorous CEO comparison.